

9 December, 2025.

## **I-SCREEN LAUNCHES IN SINGAPORE AS REGIONAL HUB FOR ASIAN EXPANSION**

**Singapore — December 9, 2025:** i-screen, Australia's leading clinical biomarker testing and bioinformatics platform, today announced the official launch of i-screen.sg, establishing Singapore as its strategic hub for expansion across Southeast Asia. The launch follows the recent appointment of Scott Montgomery as Group Chief Executive Officer and marks i-screen's first market entry into Asia.

### **Key Highlights:**

- i-screen.sg launches with focus on three core pillars: longevity testing, gut health and microbiome analysis, and comprehensive genetic screening
- Platform targets integrative health practitioners, fitness and wellness industry, insurance sector, and direct-to-consumer market across Southeast Asia
- Singapore operations rapidly attracting partners across the region, with consistent expansion into new Southeast Asian countries planned throughout 2026
- Launch capitalizes on growing longevity movement and educated health community investing in healthspan optimization

Founded in 2015, i-screen has grown to serve well over 100,000 unique users across Australia, New Zealand, and the United Kingdom, supporting a network of more than 3,500 health practitioners. With Singapore now operational, i-screen is positioned to serve the rapidly growing demand for longevity medicine, preventive care, and health optimization across Asia.

The Singapore platform delivers i-screen's full suite of clinical-grade biomarker testing including traditional pathology (blood, urine, saliva), microbiome (gut health) and genetics all through accredited laboratories. i-screen is seeking to replicate its success as the largest private pathology provider in Australia by localising for South East Asian residents.

Founder Amelia Thornycroft commented on the launch:

"Singapore is a natural first step for our Asian expansion. The market demonstrates strong alignment with our mission to make clinical-grade biomarker testing accessible, secure, and actionable. We're bringing the same evidence-based platform that has served over 100,000 users across Australia, New Zealand, and the UK to the Asian market, with a strong focus on the areas driving the future of preventive health: longevity, gut health, and genetics."

### **Serving a More Educated, Engaged Health Community**

The launch comes at a pivotal moment in preventive health. The longevity and supplement markets have experienced remarkable growth curve, driven in part by influential voices such as Dr. Peter Attia, Dr. Andrew Huberman, and biohacker Bryan Johnson. This

movement has cultivated a more educated and engaged community actively investing in their healthspan—not just lifespan.

"We're seeing a fundamental shift in how people approach their health," Montgomery noted. "Individuals are no longer waiting for symptoms to appear. They're seeking data-driven insights to optimize their health, prevent or defer disease, and extend their healthspan. This is precisely what i-screen delivers."

### **Target Industries and Partnerships**

i-screen.sg is positioned to serve many partner categories but has focused on four core healthcare and wellness verticals across the region:

**Integrative Health Practitioners** — Dietitians, nutritionists, naturopaths, Traditional Chinese Medicine (TCM) practitioners, acupuncturists, and integrative medicine specialists can combine i-screen's comprehensive testing into their practice, enabling personalized treatment protocols based on clinical biomarkers.

**Fitness & Wellness Industry** — Personal trainers, sports performance coaches, and wellness centers can leverage genetic potential, hormone panels, and biological age assessments to develop truly personalized training and recovery protocols for their clients.

**Insurance Sector** — Health insurers and corporate wellness programs can utilize i-screen's platform to support preventive care initiatives, clinical risk assessment, and potentially value-based care models to reward proactive health management.

**Direct-to-Consumer** — The platform serves the growing number of health-conscious individuals taking control of their own health optimization, driven by integrative medicine and the longevity movement to maximize their healthspan.

"With the rise of health optimization, preventive care and longevity medicine, i-screen is uniquely positioned as the region's most proven biomarker testing platform," Montgomery said. "Singapore represents an ideal gateway for our Asian expansion, with strong health literacy, advanced healthcare infrastructure, and a population increasingly focused on proactive health management. Asia's exceptional digital proficiency combined with its substantial population creates a substantial opportunity for scalable, evidence-based health solutions."

### **Longevity, Gut Health and Genetics: The Three Pillars**

i-screen.sg's offering centers on three core areas of modern preventive medicine:

**Longevity Testing** — Biological age assessments using validated blood biomarker panels, allowing individuals to understand how their body is aging compared to their chronological age. These insights support targeted interventions in areas such as metabolic health, cardiovascular function, and inflammatory markers that directly impact healthspan and longevity.

**Gut Health & Microbiome Analysis:** i-screen offers the world's most comprehensive and advanced gut health test - Microbiomix, powered by metagenomic shotgun sequencing. This technology delivers unparalleled, high-resolution insights by analyzing over 28,000 microbial species (including bacteria, fungi, and viruses), ensuring a complete 360° view of the gut ecosystem. The test goes beyond simple composition to provide functional insights into Microbial Function, Functional Markers and Screening for critical markers.

**Genetic Testing** — The DNA Comprehensive Check analyzes 111 genes and 129 SNPs across critical health categories including digestion, energy metabolism, hormones, stress and cognitive performance, inflammation and longevity, athletic performance, DNA protection and repair (methylation), and detoxification pathways. These insights enable truly personalized health optimization strategies based on individual genetic architecture.

All testing is conducted through accredited laboratories, ensuring clinical-grade accuracy and reliability. Results are reviewed by experienced health professionals and delivered through i-screen's advanced digital platform with clear, actionable insights and personalized recommendations.

### **Simple, Secure, Evidence-Based Access to Pathology Testing.**

i-screen.sg provides a streamlined user experience through its secure digital platform offering consumer access to hundreds of tests and a personalised results dashboard explaining results an average adult can understand:

1. **Order Online** – Select the appropriate health check and create a secure account
2. **Sample Collection** – Visit a local collection center or receive an at home test kit.
3. **Results & Insights** – Access results through a personalized dashboard with professional medical interpretation

Users can track biomarkers over time, monitor progress toward health goals, and access educational resources to support informed decision-making. The platform is designed for both direct-to-consumer use and integration with healthcare practitioners, supporting collaborative care models.

### **Rapid Regional Growth**

i-screen is already attracting partners in Singapore as well as proximal major cities across the region. As part of the company's strategic roadmap, Southeast Asian expansion will add new countries consistently throughout 2026, with Singapore serving as the operational foundation for broader regional growth.

Organizations across Asia seeking clinical-grade biomarker solutions for their members, patients, or policyholders can learn more at [www.i-screen.sg](http://www.i-screen.sg) or contact us at [info@i-screen.sg](mailto:info@i-screen.sg)

**About i-screen.**

i-screen is a clinical biomarker testing and bioinformatics platform providing secure, evidence-based screening from accredited blood pathology, microbiome and genetics laboratories and imaging clinics. Founded in 2015 in Western Australia, i-screen empowers individuals and healthcare practitioners with clear, actionable insights through an intuitive digital platform. With more than 100,000 users and over 3,500 practitioner partners, i-screen is Australia's largest private provider of direct-to-consumer pathology testing and a rapidly expanding leader across APAC and UK.

Australia: [www.i-screen.com.au](http://www.i-screen.com.au)

New Zealand [www.i-screen.co.nz](http://www.i-screen.co.nz)

UK [www.healthily.co.uk](http://www.healthily.co.uk)

Singapore [www.i-screen.sg](http://www.i-screen.sg)

---